Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
Strong financial position with $157.3 million; runway into 2H 2026
IK-930 program on track to deliver clinical update in 2H 2024
NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.